Biotech reporter Max Stendahl joins necn to discuss his story, "Headcount soars at Cambridge gene editing biotechs as trials near."
Biotech reporter Max Stendahl joins necn to discuss his story, "Headcount soars at Cambridge gene editing biotechs as trials near."